Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary

  

MART-1 reactive CD8+ lymphocytes 
Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor-associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:MART 1-reactive PBL
MART-1 reactive CD8-positive T lymphocytes